MaxCyte and Ori Biotech Collaborate to Improve Cell Therapy Manufacturing
Why we think this is neutral
This RNS announcement is a general update on a collaboration between MaxCyte and Ori Biotech, which does not contain any specific financial or operational details that would warrant a strong sentiment score. The announcement focuses on the companies' plans to integrate their technologies to enhance cell therapy manufacturing processes.
Key Points
- MaxCyte and Ori Biotech to integrate their respective technologies to improve cell therapy manufacturing
- The collaboration will focus on enhancing the yield and timelines for gene-edited T cell production
- The companies aim to provide therapy developers with a powerful toolkit to achieve clinically relevant quantities of gene-edited T cells more rapidly and efficiently
Summary
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a cell-engineering focused company, and Ori Biotech, a manufacturing technology company, have announced a strategic collaboration to enhance efficiency, scalability, and productivity in cell therapy manufacturing. The collaboration will integrate MaxCyte's ExPERT™ platform and Flow Electroporation® technology with Ori's IRO® next-generation manufacturing platform to optimize the yield and streamline the manufacturing timelines of gene-edited primary T cells.